Ryvu Therapeutics Announces Presentations at the AACR 2022 Annual Meeting

Krakow, Poland – April 11, 2022 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced presentations from its most advanced oncology program RVU120 and MTA-cooperative PRMT5 inhibitor program at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13 in New Orleans, U.S.

Posters to be presented at the conference will include data from RVU120, a CDK8/CDK19 inhibitor program targeting hematologic and solid tumors, and data from an MTA-cooperative PRMT5 inhibitor program.

Abstract/Poster Details:

Title: RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo
Abstract Number: 2647
Session Title: Novel Targets and Pathways
Session Date and Time: Tuesday Apr 12, 2022 9:00 AM – 12:30 PM

Title: Discovery of novel MTA-cooperative PRMT5 inhibitors as a targeted therapeutic for MTAP deleted cancers
Abstract Number: 1117
Session Title: Drug Targets
Session Date and Time: Monday Apr 11, 2022 1:30 PM – 5:00 PM

Title: Trials in Progress – RVU120 SOL-021: An open-label, single agent, Phase I/II trial of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors
Abstract Number: 8023
Session Title:  Phase II Trials in Progress
Session Date and Time: Monday Apr 11, 2022 9:00 PM – 12:30 PM